Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics, a clinical-stage cardiovascular genetic medicine company, has announced new equity awards granted to three employees on March 31, 2025. The inducement grants, made under the company's 2024 Inducement Stock Incentive Plan, include:
- Stock options to purchase 50,700 shares at $4.57 per share (closing price on grant date)
- 17,800 restricted stock units (RSUs)
The stock options have a 10-year term with a four-year vesting schedule: 25% vesting after one year, followed by monthly installments over three years. The RSUs will vest equally over three years, starting April 1, 2025. Both grants require continued employment for vesting.
Verve Therapeutics, una società di medicina genetica cardiovascolare in fase clinica, ha annunciato nuovi premi azionari concessi a tre dipendenti il 31 marzo 2025. I premi di indennizzo, concessi nell'ambito del Piano di Incentivazione Azionaria 2024 dell'azienda, includono:
- Opzioni su azioni per l'acquisto di 50.700 azioni a $4,57 per azione (prezzo di chiusura alla data di concessione)
- 17.800 unità azionarie vincolate (RSU)
Le opzioni su azioni hanno un termine di 10 anni con un programma di maturazione di quattro anni: il 25% matura dopo un anno, seguito da rate mensili per tre anni. Le RSU matureranno in modo equo per tre anni, a partire dal 1 aprile 2025. Entrambi i premi richiedono un'occupazione continuativa per la maturazione.
Verve Therapeutics, una empresa de medicina genética cardiovascular en etapa clínica, ha anunciado nuevos premios de acciones otorgados a tres empleados el 31 de marzo de 2025. Las concesiones de inducción, realizadas bajo el Plan de Incentivos de Acciones de Inducción 2024 de la empresa, incluyen:
- Opciones sobre acciones para comprar 50,700 acciones a $4.57 por acción (precio de cierre en la fecha de concesión)
- 17,800 unidades de acciones restringidas (RSUs)
Las opciones sobre acciones tienen un plazo de 10 años con un cronograma de adquisición de cuatro años: el 25% se adquiere después de un año, seguido de cuotas mensuales durante tres años. Las RSUs se adquirirán de manera equitativa durante tres años, comenzando el 1 de abril de 2025. Ambas concesiones requieren empleo continuo para la adquisición.
Verve Therapeutics는 임상 단계의 심혈관 유전자 의학 회사로, 2025년 3월 31일에 세 명의 직원에게 새로운 주식 보상을 발표했습니다. 이 유도 보상은 회사의 2024 유도 주식 인센티브 계획에 따라 이루어졌으며, 포함된 내용은 다음과 같습니다:
- 주당 $4.57(부여일의 종가)로 50,700주를 구매할 수 있는 주식 옵션
- 17,800개의 제한된 주식 단위(RSU)
주식 옵션은 10년의 기간을 가지며, 4년의 분할 일정으로 구성되어 있습니다: 1년 후 25%가 분할되고, 이후 3년 동안 매월 분할됩니다. RSU는 2025년 4월 1일부터 시작하여 3년 동안 균등하게 분할됩니다. 두 가지 보상 모두 분할을 위해 지속적인 고용이 필요합니다.
Verve Therapeutics, une entreprise de médecine génétique cardiovasculaire en phase clinique, a annoncé de nouvelles attributions d'actions à trois employés le 31 mars 2025. Les attributions d'incitation, effectuées dans le cadre du Plan d'Incentive d'Actions d'Induction 2024 de l'entreprise, comprennent :
- Des options d'achat d'actions pour acquérir 50 700 actions à 4,57 $ par action (prix de clôture à la date d'attribution)
- 17 800 unités d'actions restreintes (RSUs)
Les options d'achat d'actions ont une durée de 10 ans avec un calendrier d'acquisition de quatre ans : 25% sont acquises après un an, suivies de versements mensuels pendant trois ans. Les RSUs seront acquises de manière égale sur trois ans, à partir du 1er avril 2025. Les deux attributions nécessitent un emploi continu pour l'acquisition.
Verve Therapeutics, ein Unternehmen für genetische Medizin im kardiovaskulären Bereich in der klinischen Phase, hat am 31. März 2025 neue Aktienvergütungen an drei Mitarbeiter bekannt gegeben. Die Anreizvergaben, die im Rahmen des Aktienoptionsplans 2024 des Unternehmens gewährt wurden, umfassen:
- Aktienoptionen zum Kauf von 50.700 Aktien zu einem Preis von 4,57 $ pro Aktie (Schlusskurs am Vergabetag)
- 17.800 eingeschränkte Aktieneinheiten (RSUs)
Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem vierjährigen Vesting-Plan: 25% vesten nach einem Jahr, gefolgt von monatlichen Raten über drei Jahre. Die RSUs werden gleichmäßig über drei Jahre vesten, beginnend am 1. April 2025. Beide Vergaben erfordern eine fortgesetzte Beschäftigung für das Vesting.
- None.
- None.
BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company granted equity awards to three new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received stock options to purchase an aggregate of 50,700 shares of the company’s common stock and an aggregate of 17,800 restricted stock units (RSUs). The options have an exercise price of
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company’s lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
